... 11 12 2018 © 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2019 CCK cyclic peptides cyclotides cystine knot drug design protein–protein interactions The genomic and proteomic revolutions have provided us with an ever-increasing...

... to this work. 12 4 2017 22 6 2017 26 6 2017 27 6 2017 © 2017 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society 2017 drug design osteoclasts protein–protein interactions rational protein engineering receptor tyrosine kinases X-ray...

... sequence and conformation influence its binding kinetics, then applied this information to design new inhibitor variants for diverse protease targets. cyclic peptides drug design kallikrein-related peptidase Laskowski mechanism protease inhibitors In the present study, we used the 14 amino...

... ability to reduce exocytosis from non-neuronal cells expressing the BoNT/A-acceptor and utilising VAMP, but not SNAP-25, in exocytosis. clostridial neurotoxins drug design duration of action exocytosis protein chimaeras soluble N -ethylmaleimide-sensitive fusion protein-attachment protein...

... substrate-binding pocket in our model constituted an active conformation that was suitable for further enzymatic mechanism study and structural-based drug design against mPGES-1. © The Authors Journal compilation © 2011 Biochemical Society 2011 drug design enzyme mechanism inflammation membrane...

... ). Aurora-A kinase DFG-in DFG-out DFG-up drug design inhibitor selectivity MLN8054 Following the success of Glivec in the treatment of chronic myelogenous leukaemia, the development of small molecule kinase inhibitors has become an established goal in drug discovery [ 1 ]. A major obstacle...

... 2009 11 5 2009 © The Authors Journal compilation © 2009 Biochemical Society 2009 apoptosis CK2 inhibitor drug design homeodomain-interacting protein kinase-2 (HIPK2) provirus integration site for Moloney murine leukaemia virus 1 (PIM1) quinalizarin CK2, an acronym derived...

...) inhibitor drug design homeodomain-interacting protein kinase 2 (HIPK2) provirus integration site for Moloney murine leukaemia virus 1 (PIM1) selectivity All chemicals and solvents used for the syntheses were purchased from Sigma–Aldrich. Details for the synthesis of most benzimidazoles...

... compilation © 2008 Biochemical Society 2008 CXCR2 chemokine drug design G-protein-coupled receptor dimerization high-throughput screening imaging-based protein–protein interaction assay δ-opioid receptor The idea that GPCRs (G-protein-coupled receptors) act as monomers remains a pervasive...

... Leishmania spp. The difference in the substrate specificity of the human and Leishmania donovani glyoxalase II enzyme could be exploited for structure-based drug design of selective inhibitors against the parasite. Genomic DNA was isolated from ∼2×10 9 L. donovani AG83 promastigotes at late...

...-mail debasish@cbse.uab.edu ). 5 4 2001 8 8 2001 7 11 2001 The Biochemical Society, London ©2002 2002 drug design epilepsy glaucoma protein structure topiramate Abbreviations used: CA, carbonic anhydrase; HCA, human CA. Biochem. J. (2002) 361, 437 441 (Printed...